GGrantIndex
← Leaderboards

Witold B. Rybka

Pennsylvania State Univ Hershey Med Ctr

Google Scholar ↗PubMed ↗ORCID ↗
$244,866
Attributed
$244,866
Total exposure
22
Grants
19
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $66.7K · FY2005–09
$100K$75K$50K$25K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$244,866 · 22

By mechanism

M01$244,866 · 22

Top collaborators

No co-investigators on record.

Most similar at Pennsylvania State Univ Hershey Med Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Resources”

Research focus

ResourcesGrantSourceUnited States National Institutes Of HealthFundingInstitutionResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabasePaclitaxelProtocols DocumentationClinical TrialsCyclophosphamidePurposeMalignant Neoplasm Of BreastToxic EffectTrastuzumabClinical ResearchTumorErbb2 GeneEastern Cooperative Oncology GroupAdjuvantPositive Lymph NodeCyclophosphamide/Doxorubicin ProtocolProtein Overexpression

Grant awards (23)

CLINICAL TRIAL: PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM$18,026
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL$7,395
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET$3,235
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION$3,235
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM$34,079
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL$6,491
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION$4,463
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACL$1,217
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR MET$405
M01 · FY2008 · RR · contact PI
PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM CELL TRANSPLANT$30,132
M01 · FY2007 · RR · contact PI
A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION HODGKIN'S DIS$11,253
M01 · FY2007 · RR · contact PI
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS$5,083
M01 · FY2007 · RR · contact PI
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS$3,267
M01 · FY2007 · RR · contact PI
P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR METASTATIC BRCA EC$2,178
M01 · FY2007 · RR · contact PI
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS$39,144
M01 · FY2006 · RR · contact PI
P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS$18,927
M01 · FY2006 · RR · contact PI
PHASE 3 AML:DAUNORUBICIN DOSE INTENS &G-O CONSOL PRIOR AUTO STEM CELL TRANSPLANT$3,011
M01 · FY2006 · RR · contact PI
P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR METASTATIC BRCA EC$3,011
M01 · FY2006 · RR · contact PI
A RANDOMIZED PHASE III TRIAL OF ABVD VS STANDFORD V+/- RADIATION HODGKIN'S DIS$2,581
M01 · FY2006 · RR · contact PI
P III TRIAL OF DOXORUBICIN &CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS$23,455
M01 · FY2005 · RR
P III TRIAL OF DOXORUBICIN &CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS$14,617
M01 · FY2005 · RR
P3 PACLITAXEL +BEVACIZUMB AS 1ST-LINE THER -LOCALLY RECURROR METASTATIC BRCA EC$8,498
M01 · FY2005 · RR
Trial of Doxorubicin/Cyclophosphamide/Taxol in breast Ca$1,163
M01 · FY2004 · RR